StandardX, a UK-headquartered European deep tech company founded in 2025, has raised £10 million in seed funding to build what it describes as the world's first scalable isotope refinery. The round was led by Vsquared Ventures and East X Ventures, with additional backing from firstminute capital, UKI2S, Brevan Howard Macro Venture, and Geometry. The investment will support first production of medical isotopes and accelerate work to create a resilient supply for cancer diagnostics, treatment, and life-saving research.
A Critical Global Shortage in Isotopes
Isotopes are rare forms of chemical elements that underpin innovation across healthcare, energy, and other critical sectors. Global production capacity remains constrained, fragile, and concentrated in a small number of locations, relying on ageing facilities and output-limited machines. This supply gap is already affecting cancer care, with NHS data showing only 69.6 percent of patients received treatment within 62 days in May 2026, far below the 85 percent target unmet since December 2015.
Impact on Next-Generation Cancer Treatments
Isotopes enabling a new generation of cancer treatments, particularly targeted alpha therapies, are so scarce that clinical trials have been paused or delayed across the UK, Europe, and beyond. These therapies attack cancer cells directly while sparing the healthy tissue around tumours. StandardX aims to remove this barrier by making the necessary isotopes available at commercial scale.
The First Scalable Isotope Refinery
StandardX is building an isotope refinery designed to turn chronic scarcity into reliable and abundant supply. Its proprietary accelerator system replaces today's patchwork of narrow, isotope-specific infrastructure with deployable machines built on a standard industrial footprint. Each machine can manufacture a full portfolio of isotopes at commercial scale, supporting distributed production located close to demand.
Initial Focus on Cancer Diagnosis and Therapy
Production will begin with isotopes for cancer diagnosis and therapy, serving both hospital supply needs today and drug developers working on tomorrow's treatments. Some of these next-generation isotopes are not commercially available at any meaningful scale. StandardX expects to supply first isotopes to a medical research partner in 2027, followed by industrial-scale production from 2029.
Expanding into Fusion Energy and Tritium
The same accelerator platform will later scale to support other advanced industries, including fusion energy. Tritium, the scarce fuel used in fusion power plants, has a global inventory of only 25 kilogrammes, while a single fusion plant could require tens of kilogrammes each year. StandardX has already signed agreements with leading fusion developers to manufacture tritium and help bring fusion power to the grid.
Leadership, Team, and Operational Plans
StandardX was co-founded by Richard Pearson and Ross Allen, both nuclear engineers with experience scaling startups. The company has built a team of 15 scientists, engineers, and operators from institutions including SpaceX, Oxford University, Cambridge University, Fermilab, and the UK Atomic Energy Authority. The seed funding will help grow the team, secure the company's first industrial site in London, and advance the design and build of its first accelerator-based isotope refinery system.
Investor Confidence in a Strategic Platform
Vsquared Ventures and East X Ventures see StandardX as potential critical infrastructure for radiopharmaceuticals and fusion energy. Investors noted that radiopharma is approaching an inflection point while isotope supply has not kept pace, and that the company can build a valuable medical isotope business without relying on fusion timelines. They also highlighted London's position as a leading ecosystem for cancer research and clinical trials.
StandardX's £10 million seed round marks a significant step toward addressing a critical bottleneck in advanced medicine and clean energy. The company plans to move from concept into engineering, from physics into hardware, and from discussions into delivery. If successful, its isotope refinery could create a more resilient and sovereign supply chain for rare materials across Europe and beyond.